Aliases & Classifications for Adenocarcinoma

About this section
8Disease Ontology, 10DISEASES, 44Novoseek, 61UMLS, 56SNOMED-CT, 39NCIt, 33MeSH
See all sources

Aliases & Descriptions for Adenocarcinoma:

Name: Adenocarcinoma 8 10 44 61
Adenocarcinoma, No Subtype 8
Adenocarcinoma Nos 8
Adenocarcinomas 8


External Ids:

Disease Ontology8 DOID:299
NCIt39 C2852
MeSH33 D000230

Summaries for Adenocarcinoma

About this section
Disease Ontology:8 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary: Adenocarcinoma, also known as adenocarcinoma, no subtype, is related to colon adenocarcinoma and gastric adenocarcinoma. An important gene associated with Adenocarcinoma is EPCAM (epithelial cell adhesion molecule), and among its related pathways are Signalling to ERKs and G protein signaling K RAS regulation pathway. The drug thiotepa and the compounds panitumumab and regorafenib have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and colon, and related mouse phenotype normal.

Wikipedia:64 Adenocarcinoma (/? more...

Related Diseases for Adenocarcinoma

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 884)
idRelated DiseaseScoreTop Affiliating Genes
1colon adenocarcinoma32.5KRAS
2gastric adenocarcinoma32.5KRAS, MUC4, EPCAM
3adenoma31.8BRAF, MUC4, KRAS, CTSB
4lung cancer31.6CTSB, KRAS, MUC4, EPCAM
5cholangiocarcinoma31.2KRAS, MUC4, BRAF
6pancreatic cancer31.2EPCAM, MUC4, KRAS
7colorectal cancer31.2CTSB, KRAS, EPCAM, BRAF
8melanoma31.1BRAF, EPCAM, MUC4, MTA1, KRAS, CTSB
9lynch syndrome31.1BRAF, KRAS
10cystadenoma31.1KRAS, BRAF
11bronchiolo-alveolar adenocarcinoma31.0KRAS, MUC4
12lung cancer susceptibility 330.9CTSB, KRAS, MUC4, BRAF
13barrett esophagus/esophageal adenocarcinoma30.9ASCC1, CTHRC1
14breast cancer30.9EPCAM, MUC4, KRAS, CTSB
15endometrial cancer30.7BRAF, MUC4, KRAS
16stomach cancer30.6BRAF, MUC4, KRAS, CTSB
17ovarian cancer, somatic30.6BRAF, EPCAM, MTA1, KRAS, CTSB
18hepatitis b30.1CTSB, KRAS, MTA1
21prostate adenocarcinoma11.1
23pancreatic ductal adenocarcinoma11.1
24endometrial adenocarcinoma11.1
25mucinous adenocarcinoma11.1
26colorectal adenocarcinoma11.0
27clear cell adenocarcinoma11.0
29papillary adenocarcinoma11.0
30cervical adenocarcinoma11.0
31adenocarcinoma in situ10.9
32breast adenocarcinoma10.9
33polymorphous low-grade adenocarcinoma10.8
34small bowel adenocarcinoma10.8
37barrett's adenocarcinoma10.7
38ovarian clear cell adenocarcinoma10.7
40gallbladder adenocarcinoma10.7
42signet ring cell adenocarcinoma10.6
43endocervical adenocarcinoma10.6
44gastric cardia adenocarcinoma10.6
45urachal adenocarcinoma10.6
49gastroesophageal junction adenocarcinoma10.6
50neuroendocrine carcinoma10.6

Graphical network of the top 20 diseases related to Adenocarcinoma:

Diseases related to adenocarcinoma

Symptoms for Adenocarcinoma

About this section

Drugs & Therapeutics for Adenocarcinoma

About this section

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Abraxane13 38 PACLITAXEL Celgene; Approved October 2012;
FDA Label: Abraxane
Malady that Drug Treats: non-small cell lung cancer;
Indications and Usage:13 ABRAXANE is a microtubule inhibitor indicated for the treatment of:; Metastatic breast cancer, after failure of combination chemotherapy; for metastatic disease or relapse within 6 months of adjuvant; chemotherapy. Prior therapy should have included an anthracycline; unless clinically contraindicated. (1.1); Locally advanced or metastatic non-small cell lung cancer (NSCLC),; as first-line treatment in combination with carboplatin, in patients who; are not candidates for curative surgery or radiation therapy. (1.2); Metastatic adenocarcinoma of the pancreas as first-line treatment, in; combination with gemcitabine. (1.3)
DrugBank Targets:11 1. Apoptosis regulator Bcl-2; 2. Tubulin beta-1 chain;; 3. Nuclear receptor subfamily 1 group I member 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein 2; 6. Microtubule-associated protein tau
Mechanism of Action:13 
Target: microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules; by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule; network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or  bundles of; microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Cervarix13 38 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
FDA Label: -
Malady that Drug Treats: prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:13 -
DrugBank Targets: -
Mechanism of Action:13 
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
Cyramza13 38 RAMUCIRUMAB Eli Lilly Approved April 2014
FDA Label: Cyramza
Malady that Drug Treats: gastric cancer
Indications and Usage:13 CYRAMZA® is a human vascular endothelial growth factor receptor 2; antagonist indicated; as a single agent or in combination with paclitaxel, for treatment; of advanced gastric or gastro-esophageal junction; adenocarcinoma, with disease progression on or after prior; fluoropyrimidine- or platinum-containing chemotherapy. (1.1); in combination with docetaxel, for treatment of metastatic nonsmall; cell lung cancer with disease progression on or after; platinum-based chemotherapy. Patients with EGFR or ALK; genomic tumor aberrations should have disease progression on; FDA-approved therapy for these aberrations prior to receiving; CYRAMZA. (1.2); in combination with FOLFIRI, for the treatment of metastatic; colorectal cancer with disease progression on or after prior; therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.; (1.3)
DrugBank Targets: -
Mechanism of Action:13 
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor; 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulated; activation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of human; endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
Eloxatin13 38 OXALIPLATIN Sanofi-aventis Approved August 2002
FDA Label: Eloxatin
Malady that Drug Treats: Metastatic colon or rectum carcinomas that have recurred or progressed within six months folowing first-line treatment
Indications and Usage:13 ELOXATIN is a platinum-based drug used in combination with infusional 5-; fluorouracil /leucovorin, which is indicated for:; adjuvant treatment of stage III colon cancer in patients who have; undergone complete resection of the primary tumor. (1); treatment of advanced colorectal cancer. (1)
DrugBank Targets:11 1. DNA
Mechanism of Action:13 
Target: DNA replication and transcription
Action: inhibitor
FDA: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via; displacement of the labile oxalate ligand. Several transient reactive species are formed, including; monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both interand; intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of; two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an; intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription.; Cytotoxicity is cell-cycle nonspecific.; In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In; combination with 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity; greater than either compound alone in several tumor models [HT29 (colon), GR (mammary), and; L1210 (leukemia)].
Gardasil13 38 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006
FDA Label: Gardasil
Malady that Drug Treats: Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:13 GARDASIL is a vaccine indicated in girls and women 9 through 26; years of age for the prevention of the following diseases caused by; Human Papillomavirus (HPV) types included in the vaccine:; Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16; and 18 (1.1); Genital warts (condyloma acuminata) caused by HPV types 6 and; 11 (1.1); And the following precancerous or dysplastic lesions caused by HPV; types 6, 11, 16, and 18:; Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical; adenocarcinoma in situ (AIS) (1.1); Cervical intraepithelial neoplasia (CIN) grade 1 (1.1); Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1); Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1); Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1); GARDASIL is indicated in boys and men 9 through 26 years of age for; the prevention of the following diseases caused by HPV types included; in the vaccine:; Anal cancer caused by HPV types 16 and 18 (1.2); Genital warts (condyloma acuminata) caused by HPV types 6 and; 11 (1.2); And the following precancerous or dysplastic lesions caused by HPV; types 6, 11, 16, and 18:; Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2); Limitations of GARDASIL Use and Effectiveness:; GARDASIL does not eliminate the necessity for women to; continue to undergo recommended cervical cancer screening.; (1.3, 17); Recipients of GARDASIL should not discontinue anal cancer; screening if it has been recommended by a health care provider.; (1.3, 17); GARDASIL has not been demonstrated to provide protection; against disease from vaccine and non-vaccine HPV types to which; a person has previously been exposed through sexual activity.; (1.3, 14.4, 14.5); GARDASIL is not intended to be used for treatment of active; external genital lesions; cervical, vulvar, vaginal, and anal; cancers; CIN; VIN; VaIN, or AIN. (1.3); GARDASIL has not been demonstrated to protect against; diseases due to HPV types not contained in the vaccine. (1.3,; 14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, and; GARDASIL protects only against those vulvar, vaginal, and anal; cancers caused by HPV 16 and 18. (1.3); GARDASIL does not protect against genital diseases not caused; by HPV. (1.3); Vaccination with GARDASIL may not result in protection in all; vaccine recipients. (1.3); GARDASIL has not been demonstrated to prevent HPV-related; CIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:13 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest that; the efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Human; beings develop a humoral immune response to the vaccine, although the exact mechanism of protection; is unknown.
Gemzar13 38 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
FDA Label: Gemzar
Malady that Drug Treats: pancreatic cancer/Lung cancer
Indications and Usage:13 Gemzar® is a nucleoside metabolic inhibitor indicated:; in combination with carboplatin, for the treatment of advanced ovarian; cancer that has relapsed at least 6 months after completion of platinumbased; therapy (1.1); in combination with paclitaxel, for first-line treatment of metastatic; breast cancer after failure of prior anthracycline-containing adjuvant; chemotherapy, unless anthracyclines were clinically contraindicated; (1.2); in combination with cisplatin for the treatment of non-small cell lung; cancer (1.3); as a single agent for the treatment of pancreatic cancer (1.4)
DrugBank Targets:11 1. DNA; 2. Ribonucleoside-diphosphate reductase large subunit; 3. Thymidylate synthase; 4. UMP-CMP kinase
Mechanism of Action:13 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.; Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine; diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside; triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine; triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action; of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine; nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in; the initiation of apoptotic cell death.
Gilotrif13 38 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
FDA Label: Gilotrif
Malady that Drug Treats: metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:13 GILOTRIF is a kinase inhibitor indicated for the first-line treatment of; patients with metastatic non-small cell lung cancer (NSCLC) whose tumors; have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21; (L858R) substitution mutations as detected by an FDA-approved test (1); Limitation of Use: Safety and efficacy of GILOTRIF have not been; established in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Receptor tyrosine-protein kinase erbB-2; 3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:13 
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and; irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.; Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtype; EGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,; including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, in; patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.; Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either; overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.
Herceptin13 38 TRASTUZUMAB Genentech Approved October 1998
FDA Label: Herceptin
Malady that Drug Treats: Breast cancer/gastric cancer
Indications and Usage:13 Herceptin is a HER2/neu receptor antagonist indicated for:; the treatment of HER2 overexpressing breast cancer (1.1, 1.2).; the treatment of HER2-overexpressing metastatic gastric or; gastroesophageal junction adenocarcinoma (1.3)
DrugBank Targets:11 1. Receptor tyrosine-protein kinase erbB-2; 2. Epidermal growth factor receptor; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Complement C1s subcomponent; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c; 12. Low affinity immunoglobulin gamma Fc region receptor III-B; 13. Low affinity immunoglobulin gamma Fc region receptor III-A
Mechanism of Action:13 
Target: human epidermal growth factor receptor 2 protein (HER2)
Action: binds with strong affinity for immune response
FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.;
Iressa13 38 GEFITINIB AstraZeneca Approved May 2003
FDA Label: Iressa
Malady that Drug Treats: Non-Small-Cell Lung Cancer
Indications and Usage:13 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or; metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel; chemotherapies who are benefiting or have benefited from IRESSA.; In light of positive survival data with other agents including another oral EGFR inhibitor, physicians; should use other treatment options in advanced non-small cell lung cancer patient populations who; have received one or two prior chemotherapy regimens and are refractory or intolerant to their most; recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL; PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an; increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled; randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days; of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did; not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies; section).; Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung; cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:11 1. Epidermal growth factor receptor
Mechanism of Action:13 
Target: EGFR tyrosine kinase and other tyrosine kinases
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib; inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane; cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor; receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.; No clinical studies have been performed that demonstrate a correlation between EGFR receptor; expression and response to gefitinib.
Sutent13 38 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
FDA Label: Sutent
Malady that Drug Treats: pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:13 SUTENT is a kinase inhibitor indicated for the treatment of:; Gastrointestinal stromal tumor (GIST) after disease progression on or; intolerance to imatinib mesylate. (1.1); Advanced renal cell carcinoma (RCC). (1.2); Progressive, well-differentiated pancreatic neuroendocrine tumors; (pNET) in patients with unresectable locally advanced or metastatic; disease. (1.3)
DrugBank Targets:11 1. Platelet-derived growth factor receptor beta; 2. Vascular endothelial growth factor receptor 1; 3. Mast/stem cell growth factor receptor Kit; 4. Vascular endothelial growth factor receptor 2; 5. Vascular endothelial growth factor receptor 3; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Macrophage colony-stimulating factor 1 receptor; 8. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are; implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was; evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor; of platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and; cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary; metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.; Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRbð, VEGFR2, KIT) in tumor xenografts; expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or; inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit; growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit; PDGFRbð- and VEGFR2-dependent tumor angiogenesis in vivo.
Taxotere13 38 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
FDA Label: Taxotere
Malady that Drug Treats: breast cancer
Indications and Usage:13 TAXOTERE is a microtubule inhibitor indicated for:; Breast Cancer (BC): single agent for locally advanced or metastatic BC; after chemotherapy failure; and with doxorubicin and; cyclophosphamide as adjuvant treatment of operable node-positive BC; (1.1); Non-Small Cell Lung Cancer (NSCLC): single agent for locally; ; advanced or metastatic NSCLC after platinum therapy failure; and; ; with cisplatin for unresectable, locally advanced or metastatic; untreated NSCLC (1.2); ; Hormone Refractory Prostate Cancer (HRPC): with prednisone in; androgen independent (hormone refractory) metastatic prostate cancer; (1.3); Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for; untreated, advanced GC, including the gastroesophageal junction (1.4); Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):; with cisplatin and fluorouracil for induction treatment of locally; advanced SCCHN (1.5)
DrugBank Targets:11 1. Tubulin beta-1 chain; 2. Apoptosis regulator Bcl-2; 3. Microtubule-associated protein 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein tau; 6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:13 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is; essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the; assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This; leads to the production of microtubule bundles without normal function and to the stabilization of; microtubules, which results in the inhibition of mitosis in cells. Docetaxel s binding to microtubules; does not alter the number of protofilaments in the bound microtubules, a feature which differs from most; spindle poisons currently in clinical use.

Drug clinical trials:

Search ClinicalTrials for Adenocarcinoma

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Adenocarcinoma

About this section

Anatomical Context for Adenocarcinoma

About this section

MalaCards organs/tissues related to Adenocarcinoma:

Lung, Prostate, Colon, Breast, Cervix, Pancreas, Lymph node, Ovary, Thyroid, Liver, Endothelial, Salivary gland, Bone, Appendix, Brain, Testes, T cells, Uterus, Small intestine, Testis, Skin, Kidney, Tongue, Pituitary, Neutrophil, B cells, Bone marrow, Myeloid, Thymus, Spinal cord, Placenta, Monocytes, Smooth muscle, Nk cells, Whole blood, Eye, Heart, Spleen, Skeletal muscle, Tonsil, Fetal lung, Pancreatic islet, Pineal, Bronchial epithelium, Retina, Adrenal gland, Trachea

Animal Models for Adenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Adenocarcinoma:

idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000287310.0CTSB, CTHRC1, KRAS, MALAT1, EPB41L3, BRAF

Publications for Adenocarcinoma

About this section

Articles related to Adenocarcinoma:

(show top 50)    (show all 12336)
Inhibition of the Hedgehog pathway induces autophagy in pancreatic ductal adenocarcinoma cells. (24297612)
18F-FDG PET/CT in a case of malignant priapism secondary to metastasis from mucoid adenocarcinoma of the cecum. (23334147)
Psf3 is a prognostic biomarker in lung adenocarcinoma. (23127337)
Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. (23393166)
The "drunken honeycomb" feature of pulmonary mucinous adenocarcinoma: a diagnostic pitfall of bronchial brushing cytology. (21563323)
Is a policy of watch and wait after a complete response following neoadjuvant treatment for locally advanced rectal adenocarcinoma justified? Should we reset the limit? (24288010)
Mucinous adenocarcinoma arising from diffuse serrated adenoma of the appendix which mimics appendicular abscess. (23012662)
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? (22436573)
ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. (22348389)
Metastatic mucinous adenocarcinoma of the orbit. (21281073)
The relationship between EGFR gain and VHL loss in lung adenocarcinoma and poor patient survival. (21556796)
Phorbol 12,13 dibutyrate behaves in a tumor-inhibitory manner in esophageal adenocarcinoma cell lines. (21595773)
Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL- 1/4.1B). (21131357)
Metastatic esophageal adenocarcinoma presenting as an external auditory canal mass. (20115997)
Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. (20424616)
Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. (18798225)
Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. (19162366)
Postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma. (19396009)
Familial adenomatous polyposis-associated ampullary adenoma: response to chemotherapy for concurrent metastatic adenocarcinoma. (19245848)
Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas. (18439156)
Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. (17449965)
Expression of heparanase and nuclear factor kappa B in pancreatic adenocarcinoma]. (17715045)
A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. (17275030)
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. (17667920)
High animal-fat intake changes the bile-acid composition of bile juice and enhances the development of Barrett's esophagus and esophageal adenocarcinoma in a rat duodenal-contents reflux model. (17868414)
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. (17639508)
Endometrial adenocarcinoma and mucometra in a 6-year-old Alaska Malamute dog. (16519728)
Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. (16353209)
Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. (15753363)
Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. (15929754)
Calcified metastatic mediastinal lymph nodes from mucinous breast adenocarcinoma. (14566424)
A case of transitional cell carcinoma of the renal pelvis with adenocarcinoma producing CEA and CA19-9]. (15518131)
Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. (12895227)
Human colon adenocarcinoma in the SCID/CB6 radiation chimera is susceptible to adoptive transfer of allogeneic human peripheral blood mononuclear cells. (12590703)
Mucinous adenocarcinoma of ectopic breast tissue of the vulva. (12296762)
Maspin expression in human gastric adenocarcinoma. (12366809)
Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor. (11891197)
Parathyroid hormone-related protein production by adenocarcinoma in Barrett's esophagus patient with dermatomyositis. (11478513)
Endometrial adenocarcinoma: a primer for the generalist. (11766149)
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. (11696421)
Adenocarcinoma in situ with a small cell (endometrioid) pattern in cervical smears: a test of the distinction from benign mimics using specific criteria. (10536349)
Functional heterogeneity of colonic adenocarcinoma mucins for inhibition of Entamoeba histolytica adherence to target cells. (9561779)
p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. (9196297)
Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. (8600060)
A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. (8577704)
Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction. (7924810)
Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. (8221656)
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. (2032228)
Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. (1690076)
Small bowel adenocarcinoma and Crohn's disease. (3818257)

Variations for Adenocarcinoma

About this section

Expression for genes affiliated with Adenocarcinoma

About this section
Search GEO for disease gene expression data for Adenocarcinoma.

Compounds for genes affiliated with Adenocarcinoma

About this section

Compounds related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
idCompoundScoreTop Affiliating Genes
1panitumumab44 50 1112.6KRAS, BRAF
2regorafenib50 1111.4KRAS, BRAF
3paraffin4410.4CTSB, KRAS, EPCAM, BRAF
4o6-methylguanine4410.4KRAS, BRAF
5valine4410.4BRAF, KRAS, CTSB
6crcs4410.3KRAS, BRAF
7estrogen4410.3BRAF, MUC4, MTA1, KRAS, CTSB
8retinoic acid44 2411.3FGFBP1, CTSB, KRAS, MUC4, BRAF
9cetuximab44 50 1112.2KRAS, BRAF
10progesterone44 28 60 24 1114.1BRAF, EPB41L3, MUC4, MTA1
115fluorouracil449.9CTSB, KRAS, EPCAM

GO Terms for genes affiliated with Adenocarcinoma

About this section

Molecular functions related to Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00055159.6FGFBP1, SUPT7L, BRAF, EPCAM, EPB41L3, CHMP2A

Sources for Adenocarcinoma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet